Incretin hormones are gut-derived hormones that amplify insulin release after you eat, and they do considerably more than that single job suggests. The two main incretins, glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), are secreted by specialized cells lining the intestine and act on the pancreas, brain, stomach, heart, kidneys, and liver. Their discovery reshaped diabetes treatment and, more recently, weight management, but their biology reaches into corners of human physiology that researchers are still mapping.
The Incretin Effect
The story of incretins starts with a simple observation: swallowing glucose produces a much bigger insulin response than delivering the same amount of glucose directly into the bloodstream. This gap, sometimes called the “incretin effect,” accounts for a substantial share of the insulin your body releases after a meal. Researchers confirmed the phenomenon by matching blood glucose profiles in the same subjects after oral glucose and intravenous glucose, then measuring C-peptide secretion. The oral route consistently triggered more insulin, and the extra output was attributed to gut hormones released during digestion.1PubMed. Incretin effect potentiates beta-cell responsivity to glucose as well as to its rate of change: OGTT and matched intravenous study
Two hormones drive this effect. GIP is released mainly from K-cells concentrated in the upper small intestine, while GLP-1 comes from L-cells found further down, particularly in the jejunum and ileum.2PubMed Central. Stimulation of incretin secreting cells Both cell types respond to nutrients arriving from the stomach, especially carbohydrates and fats. The two hormones then travel through the bloodstream and converge on the pancreas, where they amplify the insulin signal that glucose itself has already started.
Where Incretins Come From and How Quickly They Disappear
K-cells and L-cells are scattered among the absorptive cells of the intestinal lining, positioned to detect nutrients almost as soon as digestion begins. Research on human tissue has confirmed that these enteroendocrine cells are found in the duodenum and jejunum, and that they respond to meal intake with measurable hormone release within about an hour.3PubMed. Intestinal CART is a regulator of GIP and GLP-1 secretion and expression The speed matters: incretins need to arrive at the pancreas while blood glucose is still climbing for the insulin boost to be useful.
What’s striking about these hormones is how fast the body breaks them down. An enzyme called dipeptidyl peptidase-4 (DPP-4), found throughout the body, chops up GLP-1 almost immediately. The natural half-life of GLP-1 in your bloodstream is roughly one minute. Even when researchers block DPP-4 with drugs designed for that purpose, GLP-1’s half-life only stretches to about five minutes.4PubMed Central. Dipeptidyl peptidase-4 inhibitors: Novel mechanism of actions GIP survives somewhat longer but is still cleared rapidly. This extreme brevity is a built-in safety feature: incretins do their work during and just after a meal, then vanish before they can push blood sugar too low. It also became the central engineering problem for drug designers trying to harness incretin biology therapeutically.
How Incretins Talk to the Pancreas
When GLP-1 reaches the pancreas, it binds to GLP-1 receptors on insulin-producing beta cells. The key feature of this interaction is glucose dependence: GLP-1 amplifies insulin secretion that is already underway because blood glucose is elevated, but it does very little when blood sugar is normal or low.5PubMed Central. GLP-1 receptor activated insulin secretion from pancreatic β-cells: mechanism and glucose dependence In practical terms, this means incretin-based treatments carry a lower risk of hypoglycemia compared to older diabetes drugs that stimulate insulin release regardless of what blood sugar is doing.
Incretins also influence the other major pancreatic hormone, glucagon, but GIP and GLP-1 do this differently. GLP-1 suppresses glucagon release from alpha cells when blood sugar is high, helping to keep glucose from climbing further. GIP does the opposite in some circumstances: during low blood sugar, it actually stimulates glucagon secretion, which raises glucose and provides a protective counterbalance.6PubMed Central. Mechanisms of action and therapeutic applications of GLP-1 and dual GIP/GLP-1 receptor agonists This glucose-dependent push-and-pull between the two hormones helps keep blood sugar within a safe range after meals.
In people with type 2 diabetes, however, that system breaks down in a specific way. GIP is still secreted in roughly normal amounts, but the beta cells become resistant to its effects, losing much of the GIP-driven second-phase insulin boost. GLP-1 secretion itself is reduced, though the beta cells still respond to GLP-1 when it is provided.7PubMed. Role of incretin hormones in the regulation of insulin secretion in diabetic and nondiabetic humans This pair of defects, reduced GLP-1 production plus resistance to GIP, explains a significant portion of why insulin secretion falters in type 2 diabetes. It also explains why GLP-1-based drugs, which sidestep the GIP resistance problem, became the therapeutic focus. Meanwhile, GIP’s behavior in alpha cells worsens: in people with type 2 diabetes, GIP stimulates glucagon secretion even when blood sugar is already high, adding to the hyperglycemia problem.8PubMed Central. The role of GIP in α-cells and glucagon secretion
Slowing the Stomach
One of GLP-1’s most noticeable effects has nothing to do with insulin directly. It slows gastric emptying, the rate at which food leaves your stomach and enters the small intestine. In one study, infusing GLP-1 extended the lag phase of solid gastric emptying from a median of roughly 20 minutes to over 90 minutes and cut the emptying rate by more than half.9PubMed. GLP-1 slows solid gastric emptying and inhibits insulin, glucagon, and PYY release in humans That slower stomach emptying blunts the post-meal glucose spike by controlling how fast nutrients reach the intestine and enter the bloodstream.
Researchers increasingly recognize GLP-1 as an “enterogastrone,” a hormone that acts as a brake on the upper digestive tract.10PubMed Central. Effects of GLP-1 and incretin-based therapies on gastrointestinal motor function This braking effect has practical consequences for anyone taking GLP-1-based medications: it contributes to the feeling of fullness after smaller meals, but it also underlies some of the most common side effects, particularly nausea and vomiting. It is also why GLP-1 receptor agonists carry surgical implications, since slower stomach emptying means food may still be present in the stomach longer than expected before procedures requiring anesthesia.11PubMed Central. GLP-1 receptor agonists and delayed gastric emptying: implications for invasive cardiac interventions and surgery
Incretins and the Brain
Both GIP and GLP-1 influence appetite and food intake by acting on neurons in the brain’s satiety centers.6PubMed Central. Mechanisms of action and therapeutic applications of GLP-1 and dual GIP/GLP-1 receptor agonists Research has shown that weight loss caused by GLP-1 receptor agonists requires GLP-1 receptors in the central nervous system. Small-molecule GLP-1 receptor agonists that can cross into the brain activate specific neurons in the arcuate nucleus, a region of the hypothalamus involved in energy balance.12PubMed Central. Glucagon-like peptide-1 receptors in the brain: controlling food intake and body weight
More recent work has pinpointed another group of GLP-1 receptor neurons in the dorsomedial hypothalamus that appear to encode “preingestive satiation,” the sense of fullness that builds even before a meal is finished. Using calcium imaging in mice, researchers showed that GLP-1 receptor agonist administration increased the activity of these neurons specifically during eating behavior. These neurons interact with hunger-promoting neurons in the arcuate nucleus in a back-and-forth that fine-tunes how much food feels like enough.13PubMed Central. GLP-1 increases preingestive satiation via hypothalamic circuits in mice and humans Activating arcuate GLP-1 receptor neurons alone is enough to suppress food intake, though interestingly, doing so did not strongly affect blood glucose levels, suggesting the appetite and glucose circuits are at least partly separable.14PubMed Central. Activation of arcuate nucleus glucagon-like peptide-1 receptor-expressing neurons suppresses food intake
Effects Beyond Blood Sugar
Incretin receptors, particularly the GLP-1 receptor, are expressed not just in the pancreas and brain but in heart muscle cells, blood vessel walls, immune cells, kidneys, and the liver. This widespread distribution explains why GLP-1’s effects ripple well beyond glucose control.
Cardiovascular Protection
GLP-1 receptor agonists lower blood pressure, reduce circulating lipids, and dampen inflammation, all of which slow atherosclerosis. Multiple cardiovascular outcome trials have shown that these drugs reduce the rate of major adverse cardiovascular events in people with type 2 diabetes.15PubMed. Glucagon-like peptide 1 receptor agonists: cardiovascular benefits and mechanisms of action At the tissue level, GLP-1 receptor signaling protects endothelial function, exerts anti-inflammatory effects on macrophages, and limits the proliferation of smooth muscle cells in artery walls, all of which contribute to slowing plaque buildup.16PubMed Central. GLP-1 receptor agonists (GLP-1RAs): cardiovascular actions and therapeutic potential GLP-1 receptor agonists also stimulate endothelial cells to produce nitric oxide, a molecule that relaxes blood vessels, and reduce oxidative stress.17PubMed Central. The benefits of GLP1 receptors in cardiovascular diseases Whether these cardiovascular benefits come from direct receptor signaling in the heart and vessels, from the indirect effects of weight loss and lower blood sugar, or from both remains an open question, since GLP-1 receptor expression in cardiovascular tissue is low.
Kidney Protection
In clinical studies, GLP-1 receptor agonists have prevented the onset of severe protein leakage into the urine and slowed the decline of kidney filtration rate in people with diabetes. Some of these protective effects appear to be independent of blood sugar control.18PubMed Central. GLP-1 Receptor Agonists and Kidney Protection Animal studies have helped clarify the mechanism: activating the GLP-1 receptor in the kidney dampens inflammation driven by advanced glycation end products, promotes a shift toward anti-inflammatory immune cell behavior, and causes distinct gene-expression changes in kidney endothelial cells, tubular cells, and podocytes that favor nutrient handling and reduced oxidative stress.19PubMed. Glucagon-like peptide-1 receptor signaling modifies the extent of diabetic kidney disease through dampening the receptor for advanced glycation end products-induced inflammation
Liver Health
Fatty liver disease has become one of the more promising targets for incretin-based drugs. GLP-1 receptor agonists improve clinical, biochemical, and histological markers of fatty liver, including liver enzymes, liver fat content measured on imaging, and in some cases, fibrosis staging.20PubMed Central. GLP-1 Receptor Agonists in Non-Alcoholic Fatty Liver Disease: Current Evidence and Future Perspectives The mechanism appears to involve enhanced liver glucose metabolism, reduced fat production inside liver cells, increased fatty acid burning, and higher levels of adiponectin, a hormone that protects against fat accumulation.21Scientific Reports. Glucagon-like peptide-1 receptor agonists improve metabolic dysfunction-associated steatotic liver disease outcomes In randomized trials of people with fatty liver disease and significant fibrosis, GLP-1 receptor agonists improved liver fat fraction, liver enzymes, blood lipids, blood pressure, and body measurements.22JHEP Reports. Efficacy and safety of GLP-1 receptor agonists in MASH with fibrosis: A systematic review and meta-analysis
From Natural Hormone to Medication
Because natural GLP-1 is destroyed in about a minute, turning it into a usable drug required significant molecular engineering. Researchers have modified both ends of the GLP-1 molecule, attached fatty acid side chains that allow it to bind to albumin in the blood (extending its circulation time), and conjugated it to large carrier molecules, all to slow degradation while preserving its ability to activate the receptor.23PubMed Central. Designing GLP-1 delivery: structural perspectives and formulation approaches for optimized therapy These engineering solutions gave rise to the GLP-1 receptor agonists now widely used: liraglutide, semaglutide, exenatide, dulaglutide, and others, each with a different duration of action.
Most GLP-1 receptor agonists are injected, but oral formulations of semaglutide achieved an unusual feat. The drug is paired with a permeation enhancer that allows it to cross the stomach lining through a transcellular route, meaning it passes directly through the cells rather than squeezing between them, with no disruption of the tight junctions that normally seal the stomach lining shut.24PubMed. Transcellular stomach absorption of a derivatized glucagon-like peptide-1 receptor agonist This was a significant technical achievement, since peptide hormones are notoriously hard to deliver orally because stomach acid and digestive enzymes destroy them.
Dual and Triple Agonists
The success of GLP-1 receptor agonists naturally led researchers to ask whether activating GIP receptors alongside GLP-1 receptors would do even more. Tirzepatide, a dual GIP/GLP-1 receptor agonist, answered that question decisively: clinical trials showed remarkable glucose lowering and weight reduction.25The Journal of Korean Diabetes. GLP-1/GIP Receptor Agonists: Mechanism of Action of Tirzepatide Interestingly, a portion of tirzepatide’s insulin-sensitizing effect could not be explained by weight loss alone, suggesting the drug has metabolic benefits beyond simply making people lighter.26The Journal of Clinical Endocrinology & Metabolism. Dual GIP and GLP-1 Receptor Agonist Tirzepatide Improves Beta-cell Function and Insulin Sensitivity in Type 2 Diabetes The fact that GIP receptors are expressed on fat tissue raises the possibility that tirzepatide may directly influence how adipose tissue stores and processes fat.
The frontier is now triple agonists that target GLP-1, GIP, and glucagon receptors simultaneously. Adding glucagon receptor activation aims to boost energy expenditure and fat burning. Retatrutide, the most studied of these triple agonists, has shown promising early results in obesity, diabetes, and fatty liver disease.27Advances in Clinical Pharmacology and Therapeutics. A Scoping Review on Recent Advances in Antidiabetic Medications: From GLP-1 Receptor Agonists to Dual and Triple Agonists Preliminary clinical trial data suggest that triple agonism may produce similar or even better glycemic control and weight loss than existing dual agonists.28PubMed. Next generation dual GLP-1/GIP, GLP-1/glucagon, and triple GLP-1/GIP/glucagon agonists: a literature review
Side Effects and the Body Composition Question
The most common complaints with GLP-1 receptor agonists are gastrointestinal: nausea, vomiting, and diarrhea. These side effects are dose-dependent, meaning they worsen at higher doses. A systematic analysis of published clinical trials found that nausea risk rose significantly with dose for long-acting GLP-1 receptor agonists, and a similar dose-dependent trend held for vomiting and diarrhea. Patients already taking metformin experienced more nausea and vomiting than those who were not.29PubMed. Occurrence of nausea, vomiting and diarrhoea reported as adverse events in clinical trials studying glucagon-like peptide-1 receptor agonists: A systematic analysis of published clinical trials These effects typically ease over weeks as the body adjusts, which is why most prescribing protocols involve gradual dose increases.
A more nuanced concern is what happens to body composition during weight loss. When you lose weight through any means, you lose some lean mass alongside fat. A network meta-analysis found that GLP-1 receptor agonists reduced fat mass by about 3 kilograms and lean mass by roughly 0.9 kilograms, with lean mass loss comprising about a quarter of total weight lost.30Metabolism. Effect of glucagon-like peptide-1 receptor agonists and co-agonists on body composition: Systematic review and network meta-analysis However, the proportion of lean mass lost varies considerably across studies, with some reporting lean mass reductions between 40 and 60 percent of total weight lost, while others show figures of about 15 percent or less.31PubMed. Changes in lean body mass with glucagon-like peptide-1-based therapies and mitigation strategies A recent meta-analysis confirmed that the decrease in lean body mass with GLP-1 receptor agonists was statistically consistent across analyses, with the effect driven mainly by liraglutide and semaglutide.32PubMed Central. GLP-1 Receptor Agonists and Musculoskeletal Outcomes: A Systematic Literature Review and Meta-Analysis The wide range in reported lean mass loss likely reflects differences in exercise habits, protein intake, starting body composition, and the specific drug used. Resistance training and adequate protein are commonly recommended to mitigate muscle loss, though clinical trials specifically testing those interventions alongside GLP-1 receptor agonists are still limited.
What Happens When You Stop
Weight regain after discontinuing GLP-1 receptor agonists has emerged as a significant concern. The physiology behind it is not a mystery: the body mounts a coordinated counterattack when weight drops. Appetite-stimulating hormones like ghrelin rise, satiety hormones like leptin and peptide YY fall, and resting energy expenditure decreases. Together, these shifts create a strong drive toward weight restoration.33PubMed Central. Rebound or Retention: A Meta-Analysis of Weight Regain After the Discontinuation of Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists and Other Anti-obesity Drugs While the drugs are active, their appetite-suppressing and gastric-slowing effects override these signals. Once they’re withdrawn, those adaptive pressures resurface. This is why many clinicians and researchers now frame obesity treatment with GLP-1 receptor agonists as a chronic therapy, not a short course.
GLP-1 Receptors and the Brain Beyond Appetite
Some of the most intriguing incretin research has nothing to do with metabolism. GLP-1 receptors are found throughout the brain, and preclinical studies have identified a long list of neuroprotective effects following their activation: protection of synapses, reduction of neuroinflammation, clearance of abnormal protein aggregates associated with Alzheimer’s and Parkinson’s disease, improved mitochondrial function, and enhanced production of brain-derived growth factors.34PubMed Central. The neuroprotective effects of glucagon-like peptide 1 in Alzheimer’s and Parkinson’s disease: An in-depth review Phase II clinical trials with GLP-1 receptor agonists like liraglutide and exenatide in people with Alzheimer’s disease have shown effects on brain connectivity, brain glucose metabolism, and markers of inflammation.35São Paulo Medical Journal. GLP-1 and neuroprotection in Alzheimer’s disease: a systematic review of randomized clinical trials The results are preliminary and the trials small, but they have generated enough signal that larger studies are underway. Whether the neuroprotective effects seen in animal models will translate into meaningful cognitive benefits for patients remains one of the more watched questions in incretin biology.